883 related articles for article (PubMed ID: 21960187)
1. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
Neovius K; Buesch K; Sandström K; Neovius M
Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
[TBL] [Abstract][Full Text] [Related]
5. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
Resch B; Müller W
Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
12. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
13. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
Mahadevia PJ; Masaquel AS; Polak MJ; Weiner LB
J Med Econ; 2012; 15(5):987-96. PubMed ID: 22574798
[TBL] [Abstract][Full Text] [Related]
14. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
[TBL] [Abstract][Full Text] [Related]
15. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
Marchetti A; Lau H; Magar R; Wang L; Devercelli G
Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
Salinas-Escudero G; Martínez-Valverde S; Reyes-López A; Garduño-Espinosa J; Muñoz-Hernández O; Granados-García V; Rely K
Salud Publica Mex; 2012; 54(1):47-59. PubMed ID: 22286828
[TBL] [Abstract][Full Text] [Related]
19. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
20. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
